← All trials
NCT02017171
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2014
- Primary completion
- Jun 1, 2019
- Completion date
- Jun 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 530
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Joslin Diabetes CenterLead sponsor
- Steno Diabetes Center CopenhagenCollaborator
- Joslin Diabetes CenterOverall official - principal investigator
- University of MinnesotaOverall official - principal investigator
- Joslin Diabetes CenterSponsor investigator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- Joslin Diabetes CenterCollaborator
- University of Colorado, DenverCollaborator
- University of MichiganCollaborator
- University of TorontoCollaborator
- University of WashingtonCollaborator
- University of MinnesotaCollaborator
- Emory UniversityCollaborator
- University of CalgaryCollaborator
- University of AlbertaCollaborator
- BCDiabetes.CaCollaborator
- The University of Texas, DallasCollaborator
- Juvenile Diabetes Research FoundationCollaborator
- Northwestern UniversityCollaborator
- Yeshiva UniversityCollaborator
- Washington University in St. LouisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.